ada yang tau nggak tempat penyembuhan penyakit herves?????tolong ya frend?

0 suara
ditanyakan 2 Mei 2012 dalam Kesehatan oleh Mas Bro (10 poin)  

   

Harap masuk atau mendaftar untuk menjawab pertanyaan ini.

2 Jawaban

0 suara
dijawab 2 Mei 2012 oleh Cun (18 poin)  
Salam tanpa panjang lebar kunjungi saja website ini biar lebih jelas dan tidak binggung dengan tulisan yang terlalu banyak http://4life-transferfactormedan.com
0 suara
dijawab 5 Mei 2012 oleh GAIRAH (4 poin)  
MENURUT CLINICAL STUDY DARI KEMENTERIAN KESEHATAN RUSSIA INI BAHWA 4LIFE TRANSFER FACTOR ADALAH YANG SANGAT DIREKOMENDASIKAN KARENA KEKUATANYA DALAM MENDONGKRAK NATURAL KILLER <NK> CELL MAMPU MENCAPAI 437% MELEBIHI KEKUATAN INTERLUKIN-2 YANG KIMIAWI ITU DAN TENTUNYA YANG TERTINGGI SECARA KEKUATAN MELAWAN VIRUS, BAKTERI, KUMAN, JAMUR, PARASIT, JUGA ABNORMAL-CELL DAN ABNORMAL-IMMUNE..

.Russian Health Ministry
Natural Killer (NK) cell activity study
Effect of Transfer Factor Advanced Formulas Containing E-XF Blends on Natural Killer (NK) Cell Activity
Independent NK Cell Study Report
by Calvin W. McCausland, Ph.D. and Emma Oganova M.D., Ph.D.
SUMMARY
STUDY DESIGN: The blinded cytotoxicity study was designed by Dr.E. Oganova and Dr. C. McCausland. The independent testing of the coded samples was done under the direction of Academician Anatoly Vorobiev,M.D., Russian Academy of Medical Sciences (RAMS) and the experimental work was conducted by Dr. M.V. Kisielevsky, Dr. E.O.Khalturina, at the Russian Cancer Research Center, RAMS.

An Interleukin-2 (IL-2) standard was used to compare effectiveness. The preparations were incubated in a COzincubator with a 5% C02 atmosphere, 100% humidity and 37° C for 24 or 48 hours. Next 30 thousand K-562 tumor cells (erythroblastic human leukemia) were introduced into the wells. (Thus, the ratio of effector and target cells was 2:1. Each sample was tested in triplicate). The preparations containing both the effector (NK cells) and target cells (K562 cancer cells) along with control wells were again incubated for 18-24 hours under the same incubator conditions.

An MTT (dye) solution was used to spectro-photometricly determine the number of viable cells remaining in each well. The cytotoxic index (CI) expressed in % is reported for each sample.
In the study activation by 4Life Transfer Factor Advanced Formula, 4Life Transfer Factor Plus Advanced Formula and IL-2 resulted in a kill rate of K562 cancer cells of 69%, 97% and 88% respectively with the 48 hour incubation period giving the greatest NK cell activation.

This study was conducted under the direction of Dr. Anatoli Vorobiev by his colleagues of the Russian Academy of Medical Science. Using established methods ofcytotoxicity testing, NK cells from humans were combined with cancer cells and divided into groups of transfer factors activated NK cells and groups ofunactivated NK cells. The objective was to find the bovine and egg transfer factor blend(s) (E-XF blends) that express the greatest NK cell activation. The results enable us to identify the most potent combination that will provide the greatest health benefits.

"The 4Life sample activated NK cell activity more than the Interleukin-2 (IL-2) drug used as the standard. Here, we now refer to your sample as the Golden Interleukin," stated Dr. Kisielevsky, Russian Academy of Medical Sciences.

We strongly believe that these results are certain to be reflected in improved human health resulting from significantly improved immune response. It is our hope that people everywhere will find that 4Life Transfer Factor Advanced Formula and 4Life Transfer Factor Plus Advanced Formula will provide safe broad-spectrum immune support that is unmatched in any other health supplement today. The Use of Transfer Factors in Various Diseases
With the diversity of existing immunomodulators capable of producing either stimulating or suppressing effect on the immune system, we chose to scientifically investigate the use of transfer factor products in pathological conditions necessitating immunocorrection.

Studies demonstrating the clinical and immunological effectiveness of Transfer Factor™ and Transfer Factor Plus® in the treatment of patients with HIV infection, hepatitis B and C, herpes, urogenital chlamydiosis, severe bacterial infections (osteomyelitis) and duodenal ulcer were carried out in different clinics of Russian Federation from 2000 through 2003.

The results of the clinical studies, included in this paper, helped to evaluate the effectiveness and safety, the duration of treatments, the doses of Transfer Factor products, and prospects of their use not only in the above mentioned diseases, but in the complex treatment of various pathological conditions.
Selamat datang di Gimana.in, Ajukan Pertanyaan dan biasanya terjawab dalam beberapa menit..
Pengguna Teraktif
bulan ini:
    Gute Mathe-Fragen - Bestes Mathe-Forum

    24,581 pertanyaan

    40,387 jawaban

    17 komentar

    19,680 pengguna

    ...